beraprost and Neointima

Hemodialysis vascular access dysfunction, mostly attributed to neointimal hyperplasia, is a major cause of morbidity and hospitalization in patients on hemodialysis. It has been reported that prostaglandin I. Fifty-five patients with end-stage renal disease who were on hemodialysis were prospectively selected for this study. Twenty-three patients were assigned to be treated with 120 µg/day of beraprost sodium, while remaining patients (n = 32) were assigned to a control group. The primary outcome was primary unassisted vascular access patency at 2 years.. The incidence of primary unassisted patency at 2 years was 83% in the beraprost sodium group and 38% in the control group (p = 0.001). Analysis of covariables indicated that this effect occurred mainly as a result of beraprost sodium administration. No life-threatening adverse event or severe bleeding was recorded in any of the groups.. Our data indicated that an oral prostaglandin I

Topics: Aged; Arteriovenous Shunt, Surgical; Epoprostenol; Female; Humans; Hyperplasia; Kidney Failure, Chronic; Male; Middle Aged; Neointima; Platelet Aggregation Inhibitors; Prospective Studies; Renal Dialysis; Secondary Prevention; Time Factors; Vascular Patency